GW Pharmaceuticals Plc American Depositary Shares
GWPH
GWPH was delisted on the 4th of May, 2021.
87 hedge funds and large institutions have $884M invested in GW Pharmaceuticals Plc American Depositary Shares in 2014 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 31 increasing their positions, 11 reducing their positions, and 16 closing their positions.
182% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 11
125% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 16
98% more capital invested
Capital invested by funds: $446M → $884M (+$438M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
28% more funds holding
Funds holding: 68 → 87 (+19)
11% less call options, than puts
Call options by funds: $45.5M | Put options by funds: $51M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$73.3M |
| 2 |
CPM
Chesapeake Partners Management
Baltimore,
Maryland
|
+$13.8M |
| 3 |
VAM
Visium Asset Management
New York
|
+$8.01M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$6.37M |
| 5 |
Jane Street
New York
|
+$6.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VHCP Management
New York
|
-$23.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$21.7M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$19.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.6M |
| 5 |
A
Abingworth
London,
United Kingdom
|
-$6.07M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TDC
101
Thompson Davis & Co
Richmond,
Virginia
| – | -$3K | -50 | Closed |
|
102
Barclays
London,
United Kingdom
| – | -$1K | -17 | Closed |
|
GWPH Hedge Fund Activity: Q2 2014 in Review
87 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q2 2014, worth a combined $884M — up 98% from $446M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new GWPH positions and 16 closed out — a net gain of 20 holders — while 31 added to existing stakes and 11 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $73.3M. The largest seller was VHCP Management, cutting an estimated $23.1M.
- 87 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q2 2014, up from 68 in Q1 2014.
- Funds reported $884M of GW Pharmaceuticals Plc American Depositary Shares stock for Q2 2014, up 98% quarter-over-quarter.
- 36 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q2 2014 and 16 closed out, a net change of +20 holders.
- The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q2 2014 was Capital Research Global Investors, an estimated $73.3M added.
- The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q2 2014 was VHCP Management, an estimated $23.1M sold.
Based on aggregated 13F filings for Q2 2014.